UBS analyst David Dai lowered the firm’s price target on enGene (ENGN) to $9 from $10 and keeps a Neutral rating on the shares following the fiscal Q1 report. The firm cites increased spending due to the LEGEND trial and launch of detalimogene in 2027 for the target cut.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- enGene price target lowered to $30 from $33 at Oppenheimer
- enGene price target lowered to $27 from $30 at Guggenheim
- Buy Rating on enGene: Detalimogene’s Competitive Efficacy, Community-Friendly Delivery, and Regulatory Momentum Support $25 Target
- enGene Strengthens Balance Sheet as Bladder Cancer Gene Therapy Nears Key 2026 Milestones
- enGene reports Q1 EPS (44c), consensus (57c)